Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Formation of pathogenic antibodies is a major problem in replacement therapies for inherited protein deficiencies. For example, antibodies to coagulation factors (‘inhibitors’) seriously complicate treatment of haemophilia. While immune tolerance induction (ITI) protocols have been developed, inhibitors against factor IX (FIX) are difficult to eradicate due to anaphylactic reactions and nephrotic syndrome and thus substantially elevate risks for morbidity and mortality. However, hepatic gene transfer with an adeno‐associated virus (AAV) serotype 8 vector expressing FIX (at levels of ≥4% of normal) rapidly reversed pre‐existing high‐titre inhibitors in haemophilia B mice, eliminated antibody production by B cells, desensitized from anaphylaxis (even if protein therapy was resumed) and provided long‐term correction. High levels of FIX protein suppressed memory B cells and increased Treg induction, indicating direct and indirect mechanisms of suppression of inhibitor formation. Persistent presence of Treg was required to prevent relapse of antibodies. Together, these data suggest that hepatic gene transfer‐based ITI provides a safe and effective alternative to eradicate inhibitors. This strategy may be broadly applicable to reversal of antibodies in different genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [160]
In the citing paper
“have been implicated in contributing to long-term transgene expression in preclinical studies (35, 160, 161) and clinical trials (162 -164).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“In two different liver directed AAV‐hF9 gene transfer clinical trials there has been no indication of B‐ or T‐cell responses directed against FIX (Manno et al, 2006; Nathwani et al, 2011).”
BackgroundSelf-citationRegulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820
Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells
Lim, H. W., Hillsamer, P., Banham, A. H., & Kim, C. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4180 · Cited by 600
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 1×
“…and that can be further minimized by use of capsid sequences engineered to reduce MHC I presentation (Markusic et al, 2010; Martino et al, 2013; Zhong et al, 2008). is a critical component of the mechanism of tolerance induction by hepatic AAV gene transfer (Hoffman et al, 2011; Cao et al,…”
Self-citationActivated CD4+CD25+ T cells selectively kill B lymphocytes
Zhao, D.-M., Thornton, A. M., DiPaolo, R. J., & Shevach, E. M. (2006) · Blood · doi:10.1182/blood-2005-11-4502 · Cited by 506
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 14×
“Published by John Wiley and Sons, Ltd on behalf of EMBO. showed anaphylactic reactions as previously published (Verma et al, 2010).”
BackgroundMethodInfluentialSelf-citationNathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394 · cited 1×
“…including those affecting hFIX half ‐ life in circulation (Metzner et al, 2009; Ostergaard et al, 2011; Peters et al, 2010) and mutants with higher speci fi c activity such as hFIX (R338L) Padua, which has 8 – 10 ‐ fold higher speci fi c activity compared to wild ‐ type hFIX (Simioni et al, 2009).”
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278 · cited 1×
“Reversal of high ‐ tier F.VIII inhibitors in congenital haemophilia A likely requires further optimization of hepatic gene expression (McIntosh et al, 2013; Sack et al, 2012; Ward et al, 2011).”
Self-citation
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Hepatic-induced tolerance can also reverse pre-existing immune responses and may be synergistic with conventional immunosuppression in treatment of autoimmune disease.(90,103,104) Finally, hepatic gene transfer with microRNA (miRNA)-regulated LV vectors can similarly induce immune tolerance (see below).”
BackgroundSelf-citationAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Clinical development of gene therapy: results and lessons from recent successes
Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 232
Self-citationMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationUpdate on clinical gene therapy for hemophilia
Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2019) · Blood · doi:10.1182/blood-2018-07-820720 · Cited by 175
Self-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Toward optimal therapy for inhibitors in hemophilia
Kempton, C. L., & Meeks, S. L. (2014) · Blood · doi:10.1182/blood-2014-05-577643 · Cited by 162
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
Puzzo, F., Colella, P., Biferi, M. G., Bali, D., Paulk, N. K., Vidal, P., Collaud, F., Simon-Sola, M., Charles, S., Hardet, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6375 · Cited by 135
Su, J., Zhu, L., Sherman, A., Wang, X., Lin, S., Kamesh, A., Norikane, J. H., Streatfield, S. J., Herzog, R. W., & Daniell, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.004 · Cited by 135
Self-citationMeliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Microglia-specific targeting by novel capsid-modified AAV6 vectors
Rosario, A. M., Cruz, P. E., Ceballos-Diaz, C., Strickland, M. R., Siemienski, Z., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G. V., Srivastava, A., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.26 · Cited by 118
Gene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
Immune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
Self-citationKeeler, G. D., Kumar, S., Palaschak, B., Silverberg, E. L., Markusic, D. M., Jones, N. T., & Hoffman, B. E. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.001 · Cited by 97
Self-citationCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Sherman, A., Su, J., Lin, S., Wang, X., Herzog, R. W., & Daniell, H. (2014) · Blood · doi:10.1182/blood-2013-10-528737 · Cited by 94
Self-citationA Molecular Revolution in the Treatment of Hemophilia
Butterfield, J. S. S., Hege, K. M., Herzog, R. W., & Kaczmarek, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.006 · Cited by 94
Self-citationRogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85
Self-citationMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
Kumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83
“Foxp3 mice on C57BL/6 background were as published previously.(13,69) All mice were housed in specific pathogenfree conditions in the animal facility at the University of Florida, and all procedures were performed as per the guidelines of Institutional Animal Care and Use Committee.”
BackgroundMethodSelf-citationLiver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
“To test this hypothesis, we showed that AAV8-F9 liver gene transfer was capable of reversing pre-existing pathogenic antibodies to FIX and resulted in the long-term desensitization of anaphylaxis prone hemophilia B mice, even when protein replacement therapy was resumed [14].”
BackgroundSelf-citationHan, S.-O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.010 · Cited by 78
“Subsequently, two groups showed that expression of coagulation factor IX could similarly induce immune tolerance following inhibitory antibody formation in mice with hemophilia.(21,22) Similar effects have been demonstrated following AAV vector administration in mice and dogs with hemophilia B using a high activity fa…”
BackgroundColella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
Quintavalle, G., Castaman, G., Baldacci, E., Ferretti, A., Riccardi, F., Tagliaferri, A., & Santoro, C. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1660817 · Cited by 82
Development of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
Self-citationGene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
Herzog, R. W., Nichols, T. C., Su, J., Zhang, B., Sherman, A., Merricks, E. P., Raymer, R., Perrin, G. Q., Häger, M., Wiinberg, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.009 · Cited by 65
Self-citationEx Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia
Sarkar, D., Biswas, M., Liao, G., Seay, H. R., Perrin, G. Q., Markusic, D. M., Hoffman, B. E., Brusko, T. M., Terhorst, C., & Herzog, R. W. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.30 · Cited by 62
Self-citationFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Self-citationA Novel Platform for Immune Tolerance Induction in Hemophilia A Mice
Merlin, S., Cannizzo, E. S., Borroni, E., Bruscaggin, V., Schinco, P., Tulalamba, W., Chuah, M. K., Arruda, V. R., VandenDriessche, T., Prat, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.029 · Cited by 59
Wang, X., Su, J., Sherman, A., Rogers, G. L., Liao, G., Hoffman, B. E., Leong, K. W., Terhorst, C., Daniell, H., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-08-597070 · Cited by 58
Self-citationAnnoni, A., Cantore, A., Della Valle, P., Goudy, K., Akbarpour, M., Russo, F., Bartolaccini, S., D'Angelo, A., Roncarolo, M. G., & Naldini, L. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302857 · Cited by 58
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Self-citationAdvances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 92
Doerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 54
Self-citationBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Targeted approaches to induce immune tolerance for Pompe disease therapy
Doerfler, P. A., Nayak, S., Corti, M., Morel, L., Herzog, R. W., & Byrne, B. J. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.53 · Cited by 51
Self-citationInnate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“70 In summary, at least two distinct pathways exist that promote CD8 + T cell activation upon AAV gene transfer by conditioning of cDCs with cytokines (Fig.”
Self-citationRogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
“IX in this strain despite the gene deletion mutation [4,56,57].”
BackgroundSelf-citationHemophilia Gene Therapy: The End of the Beginning?
Wolf, D. D., Singh, K., Chuah, M., & VandenDriessche, T. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.112 · Cited by 50
Arjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Lessons learned from lung and liver in-vivo gene therapy: implications for the future
van Haasteren, J., Hyde, S. C., & Gill, D. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1506761 · Cited by 47
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
Perrin, G. Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y. P., Terhorst, C., Davidoff, A. M., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.83 · Cited by 40
Self-citationHerzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
Self-citationAAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Self-citationIn vivo induction of regulatory T cells for immune tolerance in hemophilia
Wang, X., Terhorst, C., & Herzog, R. W. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.10.001 · Cited by 39
Self-citationGene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Self-citationBrendel, C., Río, P., & Verhoeyen, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113711 · Cited by 41
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Self-citationInnovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
Self-citationNew approaches to gene and cell therapy for hemophilia
Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y., & Nishimura, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12926 · Cited by 30
Ferla, R., Claudiani, P., Savarese, M., Kozarsky, K., Parini, R., Scarpa, M., Donati, M. A., Sorge, G., Hopwood, J. J., Parenti, G., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.109 · Cited by 35
Chung, C. W., Kudchodkar, S. B., Chung, C. N., Park, Y. K., Xu, Z., Pardi, N., Abdel‐Mohsen, M., & Muthumani, K. (2023) · Antibodies · doi:10.3390/antib12030046 · Cited by 40
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
“platelet-targeted gene expression) or even eradicate pre-existing factor IX inhibitors (as has been demonstrated via hepatic expression following AAV or lentivirus factor IX gene delivery) [55] [56] [18] [49].”
BackgroundLiao, G., O’Keeffe, M. S., Wang, G., van Driel, B., Malefyt, R. D. W., Reinecker, H., Herzog, R. W., & Terhorst, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00035 · Cited by 32
Self-citationHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Wang, X., Moghimi, B., Zolotukhin, I., Morel, L. M., Cao, O., & Herzog, R. W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.43 · Cited by 31
Self-citationAn Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Sun, J., Shao, W., Chen, X., Merricks, E. P., Wimsey, L., Abajas, Y. L., Niemeyer, G. P., Lothrop, C. D., Monahan, P. E., Samulski, R. J., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.011 · Cited by 30
Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin
Sherman, A., Byrne, B. J., Markusic, D. M., Jiang, H., Biswas, M., Rogers, G. L., & Herzog, R. W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0404 · Cited by 31
Self-citationThe immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
“Inhibitor Eradication via Liver-Directed AAV-fVIII Gene Therapy? Recently, two independent groups demonstrated in a murine hemophilia B preclinical model that liver-directed AAV- or LV-fIX gene transfer can eradicate anti-fIX inhibitors and provide phenotypically-corrective plasma fIX activity (118, 126).”
BackgroundB cell–activating factor modulates the factor VIII immune response in hemophilia A
Doshi, B. S., Rana, J., Castaman, G., Shaheen, M. A., Kaczmarek, R., Butterfield, J. S. S., Meeks, S. L., Leissinger, C., Biswas, M., & Arruda, V. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142906 · Cited by 33
Jiménez‐Yuste, V., Auerswald, G., Benson, G. M., Dolan, G., Hermans, C. R. J. R., Lambert, T., Ljung, R. C. R., Morfini, M., Santagostino, E., & Šalek, S. Z. (2021) · Haemophilia · doi:10.1111/hae.14167 · Cited by 29
Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
Nayak, S., Doerfler, P. A., Porvasnik, S., Cloutier, D., Khanna, R., Valenzano, K., Herzog, R. W., & Byrne, B. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098336 · Cited by 29
Self-citationBiswas, M., Palaschak, B., Kumar, S. R. P., Rana, J., & Markusic, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01293 · Cited by 28
Self-citationToward optimal therapy for inhibitors in hemophilia
Kempton, C. L., & Meeks, S. L. (2014) · Hematology · doi:10.1182/asheducation-2014.1.364 · Cited by 28
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 30
Liver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
Brunetti‐Pierri, N., Ferla, R., Ginocchio, V. M., Rossi, A., Fecarotta, S., Romanò, R., Parenti, G., Yıldız, Y., Zancan, S., Pecorella, V., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200052 · Cited by 30
Lytle, A. M., Brown, H. C., Paik, N. Y., Knight, K. A., Wright, J. F., Spencer, H. T., & Doering, C. B. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.56 · Cited by 25
Poupiot, J., Costa Verdera, H., Hardet, R., Colella, P., Collaud, F., Bartolo, L., Davoust, J., Sanatine, P., Mingozzi, F., Richard, I., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.012 · Cited by 24
Haemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Bartolo, L., Li Chung Tong, S., Chappert, P., Urbain, D., Collaud, F., Colella, P., Richard, I., Ronzitti, G., Demengeot, J., Gross, D. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127008 · Cited by 23
Immune complications and their management in inherited and acquired bleeding disorders
Arruda, V. R., Lillicrap, D., & Herzog, R. W. (2022) · Blood · doi:10.1182/blood.2022016530 · Cited by 21
Self-citationValentino, L. A., Ozelo, M. C., Herzog, R. W., Key, N. S., Pishko, A. M., Ragni, M. V., Samelson‐Jones, B. J., & Lillicrap, D. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.011 · Cited by 21
Self-citationWang, X., Herzog, R. W., Byrne, B. J., Kumar, S. R. P., Zhou, Q., Buchholz, C. J., & Biswas, M. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.005 · Cited by 18
Self-citationEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
Self-citationTolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 17
Self-citationCell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies
Baik, A. D., Calafati, P., Zhang, X., Aaron, N. A., Mehra, A., Møller-Tank, S., Miloscio, L., Praggastis, M., Giovannone, N., Pan, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.020 · Cited by 21
Kumar, S. R. P., Xie, J., Hu, S., Ko, J., Huang, Q., Brown, H. C., Srivastava, A., Markusic, D. M., Doering, C. B., Spencer, H. T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.001 · Cited by 16
Self-citationAlliegro, M., Ferla, R., Nusco, E., Leonibus, C. D., Settembre, C., & Auricchio, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.181 · Cited by 15
Innovating immune tolerance induction for haemophilia
Batsuli, G. M., Meeks, S. L., Herzog, R. W., & Lacroix‐Desmazes, S. (2016) · Haemophilia · doi:10.1111/hae.12989 · Cited by 15
Self-citationImmune tolerance induction by hepatic gene transfer: First-in-human evidence
Kaczmarek, R., Samelson‐Jones, B. J., & Herzog, R. W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.016 · Cited by 15
Self-citationTherapeutic Advances in Hematology
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Cited by 13
Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer
Laurent, M., Harb, R., Jenny, C., Oustelandt, J., Jimenez, S., Cosette, J., Landini, F., Ferrante, A., Corre, G., Vujić, N., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00816-8 · Cited by 13
Sack, B. K., Wang, X., Sherman, A., Rogers, G. L., & Markusic, D. M. (2014) · Haemophilia · doi:10.1111/hae.12522 · Cited by 10
Self-citationInduction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors
Young, G. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013000 · Cited by 10
Bertolini, T. B., Herzog, R. W., Kumar, S. R. P., Sherman, A., Rana, J., Kaczmarek, R., Yamada, K., Arisa, S., Lillicrap, D., Terhorst, C., et al. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104675 · Cited by 10
Self-citationThe Role of Rixubis™ in the Treatment of Hemophilia B
Valentino, L. A. (2014) · Immunotherapy · doi:10.2217/imt.14.17 · Cited by 6
Protein S: A multifunctional anticoagulant
Dorsey, A. W., Pilli, V. S. S., Fried, H. M., & Majumder, R. (2017) · Biomedical Research and Clinical Practice · doi:10.15761/brcp.1000151 · Cited by 6
Schroeder, J. A., Chen, J., Chen, Y., Cai, Y., Yu, H., Mattson, J. G., Monahan, P. E., & Shi, Q. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004071 · Cited by 7
Brimble, M. A., Morton, C. L., Winston, S. M., Reeves, I. L., Spence, Y., Cheng, P.-H., Zhou, J., Nathwani, A. C., Thomas, P. G., Souquette, A. H., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.188 · Cited by 7
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Single-dose AAV vector gene immunotherapy to treat food allergy
Gonzalez-Visiedo, M., Li, X., Muñoz-Melero, M., Kulis, M. D., Daniell, H., & Markusic, D. M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.008 · Cited by 4
Self-citationEgorova, T. V., Piskunov, A. A., & Poteryaev, D. A. (2024) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2024-24-2-123-139 · Cited by 5
Viral Vector Based Immunotherapy for Peanut Allergy
Gonzalez-Visiedo, M., Herzog, R. W., Muñoz-Melero, M., Blessinger, S. A., Cook‐Mills, J. M., Daniell, H., & Markusic, D. M. (2024) · Viruses · doi:10.3390/v16071125 · Cited by 5
Self-citation
Metadata
- Authors
- Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W.
- Affiliations
- University of Florida Health (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-09-16
- Volume
- 5
- Issue
- 11
- Pages
- 1698-1709
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3840486
- OpenAlex
- W2158153222
- Cited by
- 116
- References
- 64
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 11 · 2017: 20 · 2016: 12 · 2015: 11 · 2014: 13 · 2013: 2
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (P01 HD078810 (KAH and RWH), R01 AI051390 (RWH), F32 HL096281 (DMM))
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, factor IX inhibitors, immune tolerance induction, AAV8, hepatic gene transfer, gene therapy, memory B cells, regulatory T cells, anaphylaxis, factor replacement therapy
- MeSH terms
- Dependovirus, Animals, Antibodies, Antibody Formation, B-Lymphocytes, Hemophilia B, Factor IX, Genetic Vectors, Humans, Liver, Male, Mice, Inbred C3H, Mice, Inbred C57BL, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.